Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
bRbnn7vW5panWrWj
